Search hospitals

>

Louisiana

>

Baton Rouge

Our Lady of the Lake Physicians Group - Medical Oncology

Claim this profile

Baton Rouge, Louisiana 70809

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

81 reported clinical trials

2 medical researchers

Photo of Our Lady of the Lake Physicians Group - Medical Oncology in Baton RougePhoto of Our Lady of the Lake Physicians Group - Medical Oncology in Baton RougePhoto of Our Lady of the Lake Physicians Group - Medical Oncology in Baton Rouge

Summary

Our Lady of the Lake Physicians Group - Medical Oncology is a medical facility located in Baton Rouge, Louisiana. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Our Lady of the Lake Physicians Group - Medical Oncology is involved with conducting 81 clinical trials across 132 conditions. There are 2 research doctors associated with this hospital, such as Marshall P. Stagg and David S. Hanson.

Area of expertise

1

Lung Cancer

Global Leader

Our Lady of the Lake Physicians Group - Medical Oncology has run 17 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage IV
Stage I
2

Breast Cancer

Global Leader

Our Lady of the Lake Physicians Group - Medical Oncology has run 15 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Our Lady of the Lake Physicians Group - Medical Oncology

Ovarian Cancer

Lung Cancer

Cancer

Breast Cancer

Uterine Cancer

Breast cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Bladder Cancer

Fallopian Tube Cancer

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Biobank Collection

for Cancer

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Recruiting

1 award

N/A

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Our Lady of the Lake Physicians Group - Medical Oncology?